Company Overview and News

13
NZ shares dip in market lull during US-North Korea summit

2018-06-12 nzherald.co.nz
New Zealand shares dipped in light trading as some stocks gave up dividends, with the focus on the US-North Korea summit in Singapore.
KTHDY SKT SYKWF RHCGF THL RYHTY SNZ SKKTY RYM KMD SML KMD

4
MARKET WRAP: NZ shares rise on A2, Synlait and F&P trading

2018-06-05 nbr.co.nz
New Zealand shares rose today on A2 and Synlait Milk gains, as well as a strong result for Fisher & Paykel Healthcare.
THL SML

14
Shares rise in heavy MSCI trading

2018-05-31 nzherald.co.nz
New Zealand shares rose in heavy trading as several stocks entered MSCI indices, with new entrant Synlait Milk leading gains alongside Mercury NZ. A2 Milk Co fell.
SKT SYKWF THL ANZLY AIR SKKTY ANZFF ANZFY MEZ AIZ SML

27
Shares up as Comvita, A2 rebound from weakness, Steel & Tube keeps dropping

2018-05-25 nzherald.co.nz
New Zealand shares gained as Comvita and A2 Milk Co recovered from selling, while Air New Zealand and Steel & Tube Holdings fell.
NMR FBU AIR FCREY SPKKY NZTCY SPK NZTCF FRCEF ANZFY AIZ VIL 8604 SKC N33 FBU THL ANZLY NRSCF ANZFF SML

16
Honey products exporter Comvita leads sharemarket down

2018-05-21 nzherald.co.nz
New Zealand shares dropped, led lower by Comvita as its possible takeover failed, with A2 Milk continuing last week's losses and Kiwi Property Group dropping on its earnings.
KTHDY NMR SPKKY NZTCY SPK NZTCF KWIPF KMD 8604 N33 THL NRSCF KMD SML

16
MARKET WRAP: MSCI index reshuffle - the winners and losers

2018-05-15 nbr.co.nz
An MSCI index reshuffle sent shares for Fletcher Building soaring after it survived, but Mercury Energy shares fell as it was culled from the index.
FBU FBU THL ANZLY AIR FCREY ANZFF ANZFY FRCEF AIZ SML

16
Shares dip from record; Air NZ and Mercury fall

2018-05-15 nzherald.co.nz
New Zealand shares dipped from a record high, with Air New Zealand and Mercury New Zealand falling while Synlait Milk and Fletcher Building gained.
FBU FBU THL ANZLY AIR FCREY ANZFF ANZFY FRCEF AIZ SML

11
A2 to join MSCI main stock index as Mercury drops off

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

11
Fletcher gains as stock stays in MSCI main index

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

2
NZ stocks hit new highs despite simmering US 10 year bond

2018-05-10 nzherald.co.nz
The New Zealand share market pushed on to another record high this week despite the influential US-10 year bond yield continuing its flirtation with the all-important 3 per cent.
MRNRF THL

8
NZ shares up, Sky TV bounces with Comvita

2018-04-06 nzherald.co.nz
New Zealand shares gained, led by Sky Network Television bouncing back and Orion Health surging 20 per cent after it confirmed it's considering sale options.
SKT TME TRMEF SYKWF THL TME SNZ SKKTY TDMEY SML

2
What correction? New Zealand sharemarket hits record high

2018-03-13 nzherald.co.nz
The S&P/NZX 50 stockmarket index has fully recovered from February's turmoil, hitting a record high today.
THL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to NZX:THL / Tourism Holdings on message board site Silicon Investor.

EARTHLINK (ELNK) Kathleen Willey blasts Hillaryu0027s u0027dead brokeu0027 claim
ELNK: EarthLink, Inc. Aethlon Medical BSEQ
Worthless Stock Certificates Worthless New Subjects
Athlone Minerals Ltd. Northland Power
WTHL - Whitehall Enterprises Flag Telecom Holdings - FTHL